公开(公告)号：US20200317665A1

公开(公告)日：2020-10-08

申请号：US16835702

申请日：2020-03-31

Applicant: Array BioPharma Inc.

Inventor： James F. BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam W. COOK ,  Mohamed S. A. ELSAYED ,  Jay Bradford FELL ,  John P. FISCHER ,  Ronald Jay HINKLIN ,  Yutong JIANG ,  Oren T. MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina E. WONG

IPC: C07D471/04 ,  C07D401/14 ,  C07D513/10 ,  C07D471/10 ,  A61P35/00

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20200339579A1

公开(公告)日：2020-10-29

申请号：US16962305

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： Shane M. WALLS ,  LI REN ,  Ginelle A. RAMANN ,  David A. MORENO ,  Andrew T. METCALF ,  Elizabeth A. MCFADDIN ,  Gabrielle R. KOLAKOWSKI ,  James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN

IPC: C07D471/04 ,  C07F9/6561

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220313676A1

公开(公告)日：2022-10-06

申请号：US17108528

申请日：2020-12-01

Applicant: Array Biopharma Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  James COLLIER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Ginelle A. RAMANN ,  Tony P. TANG ,  Li REN ,  Shane M. WALLS

IPC: A61K31/4545 ,  A61K31/4162 ,  C07D471/04 ,  A61P1/00 ,  A61P35/00 ,  A61P35/02 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P1/12

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20200339589A1

公开(公告)日：2020-10-29

申请号：US16962345

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Andrew T. METCALF ,  David A. MORENO ,  Brett PRIGARO ,  Ginelle A. RAMANN ,  Li REN

IPC: C07D487/04

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20240124453A1

公开(公告)日：2024-04-18

申请号：US18512473

申请日：2023-11-17

Applicant: Array BioPharma Inc.

Inventor： James Francis BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam Wade COOK ,  Mohamed S. A. ELSAYED ,  Jay Bradford FELL ,  John P. FISCHER ,  Ronald Jay HINKLIN ,  Yutong JIANG ,  Oren Teague MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina Elizabeth WONG

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10 ,  A61K45/06

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20220251083A1

公开(公告)日：2022-08-11

申请号：US17720070

申请日：2022-04-13

Applicant: Array BioPharma Inc.

Inventor： James Francis BLAKE ,  Mark Laurence BOYS ,  Mark Joseph CHICARELLI ,  Adam Wade COOK ,  Mohamed S. A. ELSAYED ,  Jay Bradford FELL ,  John P. FISCHER ,  Ronald Jay HINKLIN ,  Yutong JIANG ,  Oren Teague MCNULTY ,  Macedonio J. MEJIA ,  Martha E. RODRIGUEZ ,  Christina Elizabeth WONG

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14 ,  C07D471/10 ,  C07D513/10

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20220112214A1

公开(公告)日：2022-04-14

申请号：US17274990

申请日：2019-09-06

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. BLAKE ,  Donghua DAI ,  Julia HAAS ,  Yutong JIANG ,  Dean KAHN ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Andrew T. METCALF ,  David A. MORENO ,  Brett PRIGARO ,  Ginelle A. RAMANN ,  Li REN ,  Shane M. WALLS ,  Hailong ZHANG

IPC: C07D498/22 ,  C07D513/22 ,  C07D498/14 ,  A61K45/06 ,  A61K31/554 ,  A61K31/55 ,  A61K31/519 ,  C07D487/14 ,  A61P35/00

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20240066029A1

公开(公告)日：2024-02-29

申请号：US18342314

申请日：2023-06-27

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. Blake ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

CPC classification number: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20230090520A1

公开(公告)日：2023-03-23

申请号：US17530702

申请日：2021-11-19

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220119396A1

公开(公告)日：2022-04-21

申请号：US17514684

申请日：2021-10-29

Applicant: Array BioPharma Inc.

Inventor： Steven W. ANDREWS ,  James F. BLAKE ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  David A. MORENO ,  Li REN ,  Shane M. WALLS

IPC: C07D487/04

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.